Comparative Pharmacology

Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MANNITOL 15 W DEXTROSE 5 IN SODIUM CHLORIDE 0 45.

Peer-Reviewed Evidence

Differential Analysis

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

Electrolyte

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Mannitol increases plasma osmolality, drawing water from tissues into the intravascular space via osmotic gradient, thereby reducing intracranial pressure and promoting diuresis. Dextrose provides caloric support. Sodium chloride provides electrolytes.

Clinical Dosing

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Intravenous: 50 to 100 g (333-667 mL) initially, then 50 g (333 mL) every 4-6 hours to maintain urine output of 30-50 mL/hr. Administer as a 15% solution with dextrose 5% in 0.45% sodium chloride.

Direct Interaction

None Documented